TABLE 1.

 Mutations in the HIV-1 RT gene and antiviral drug susceptibilities observed for 13 patients with uncontrolled HIV-1 replication treated with 10 mg of ADV for lamivudine-resistant HBV infection

Patient	Time (mo)a	HIV-1 RNA copies/ml	Mutation in the HIV-1 RT geneb												Other mutations	Nucleoside analogsc given with ADV	Adefovir IC50d (μM)
			M41	E44	D67	T69	K70	L74	V75	V118	M184	L210	T215	K219
1	0	4,603			N	D	R				V		V/A	Q		D4T + 3TC	32
	7	257,772			N	D	R				V		V	Q
	12	187,000			N	D	R				V		V	Q	V60I		29
2	0	1,498			N		R				V			Q		AZT + 3TC + ddI	35
	6	1,123			N		R				V			Q	K64R
	12	369			N		R				V			Q	K64R		41
3	0	10,183	L		N		R	I			V		Y	E		AZT + 3TC + ABC	40
	3	18,845	L		N		R	I			V		Y	E	K82R, D110N, H198P, T200A
	6	15,213	L		N		R	I			V	W	Y	E	S166G
	12	9,794	L		N		R	I			V	W	Y	E	S166V		46
4	0	4,223									V					d4T + 3TC	10
	3	2,712									V				1142V, S162N
	6	6,917									V
	12	4,052					R				V				T39P		4.4
5	0	3,635									V					d4T + 3TC	7.8
	3	3,027									V	V		R	135L
	6	88,373									V			R	135L		11
6	0	3,080	L		N			V			V	W	Y			d4T + 3TC	37
	3	1,475	L		N			V			V	W	Y
	6	1,771	L		N				I		V	W	Y		V90I
	12	2,000	L		N				I		V	W	Y				43
7	0	17,679	L								V	W	Y			d4T + 3TC	25
	3	22,556	L								V	W	Y		D186Y	(d4T→ddI)
	6	21,891	L	D	N					I	V	W	Y		K43E		38
8	0	9,425	L			D					V	W	Y			d4T + 3TC	20
	6	5,870	L			D					V	W	Y	R	1142V, F214L		22
9	0	1,228									V					d4T + 3TC	6
	3	78,358									V						8
10	0	1,169						V			V					ddI + 3TC	9
	6	<200	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	12	325						V			V				T39P, T200A		11
11	0	81,548	L					V			V	W	Y	Q		d4T + 3TC + ddC	32
	3	45,662	L					V			V	W	Y	Q	1202V
	6	54,258	L					V			V	W	Y		1202V
	12	13,257	L					V			V	W	Y		H221Y		23
12	0	13,616	L		N		R				V		F	E		d4T + 3TC	28
	3	9,621	L		N		R			M	V		F	E
	6	7,167	L		N		R			I	V		F	E			35
13	0	83	L					V			V		Y	E		ddI + 3TC	20
	3	1,209	L					V			V		Y	N
	6	3,023	L					V			V		Y	E	1202V		18

^a0, baseline.

^bBoldfaced mutations were selected during follow-up. NA, nonamplifiable.

^cd4T, stavudine; 3TC, lamivudine; AZT, zidovudine; ddI, didanosine; ABC, abacavir; ddC, zalcitabine.

^dIC₅₀, 50% inhibitory concentration. Values are averages for four independent experiments; average standard errors were <10%.